glp-1 and sarcopenia Strategies to prevent loss of muscle mass in patients using GLP- 1 Do GLP-1 medications really cause

[DOI] [PMC free article] [PubMed] [Google Scholar] 220.Zhang F., et al

These factors should be evaluated individually with your healthcare provider

Recent studies have highlighted the effectiveness of weight loss medications , particularly GLP-1 agonists like Semaglutide (found in Wegovy and Ozempic) and Tirzepatide (found in Mounjaro and Zepbound), in treating obesity-related conditions

Studies have shown that GLP-1 agonists can trigger effects in the brain, the heart, the liver, the pancreas, the stomach, and the musclesmeaning that they could have implications for conditions other than type 2 diabetes and obesity, such as heart disease, kidney disease, liver disease, and even neurological conditions such as Alzheimer's disease

47,48 Human studies yield somewhat mixed results regarding the impact of GIP on bone metabolism

Both treatment approaches resulted in a mean weight loss at 52 weeks, with oral semaglutide treatment resulting in a mean weight loss from baseline of 3.8 kg and 4.7 kg in the treatment-policy estimand and trial-product estimand analyses, respectively